Drugs / WPV01
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07080658 | Jul 2023 | COVID-19 | Westlake Pharmaceuticals (Hangzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06205329 | Oct 2022 → Mar 2023 | — | Westlake Pharmaceuticals (Hangzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05752175 | Mar → May 2023 | COVID-19 | Westlake Pharmaceuticals (Hangzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06197217 | Jun → Aug 2023 | — | Westlake Pharmaceuticals (Hangzhou) Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WPV01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06205329 ↗ |
| Route | Oral | “receive WPV01 600mg orally” NCT06197217 ↗ |